

1 **Whole genome analysis reveals the genomic complexity in metastatic cutaneous squamous**
2 **cell carcinoma**

3
4 **AUTHORS AND AFFILIATIONS**

5 Amarinder S. Thind^{1,2}, Bruce Ashford^{1,2,3}, Dario Strbenac⁴, Ruta Gupta⁵, Jonathan R Clark^{4,6,7},
6 N. Gopalakrishna Iyer⁸, Jenny Mitchell³, Jenny Lee^{9,10}, Simon A Mueller^{7,11}, Elahe Minaei^{2,12},
7 Jay R. Perry^{2,12} and Marie Ranson^{2,12}

8
9 ¹School of Medicine, University of Wollongong, Wollongong, NSW, Australia

10 ²Illawarra Health and Medical Research Institute, Wollongong, NSW, Australia

11 ³Illawarra Shoalhaven Local Health District Wollongong, NSW, Australia,

12 ⁴Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, NSW,
13 Australia

14 ⁵Anatomical Pathology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.

15 ⁶Royal Prince Alfred Institute of Academic Surgery, Sydney Local Health District, Sydney, NSW,
16 Australia

17 ⁷Department of Head and Neck Surgery, Chris O'Brien Lifecare, Sydney, NSW, Australia

18 ⁸National Cancer Center, Singapore

19 ⁹Department of Medical Oncology, Chris O'Brien Lifecare, Sydney, NSW, Australia

20 ¹⁰Department of Clinical Medicine, Macquarie University, Sydney, NSW, Australia

21 ¹¹Department of Otorhinolaryngology, Head and Neck Surgery, Zurich University Hospital and
22 University of Zurich, Zurich, Switzerland

23 ¹²School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW,
24 Australia

25
26 **CORRESPONDENCE**

27 A/Prof Bruce Ashford

28 bruceash@uow.edu.au

29 372 Crown St, Wollongong, New South Wales, Australia 2500

30 +61 2 42266111

31 **Key words:** whole genome sequencing, cutaneous squamous cell carcinoma, metastases, non-
32 coding mutations, UTR, cSCC

33

34 **ABSTRACT**

35 Metastatic cutaneous squamous cell carcinoma (cSCC) is a highly morbid disease requiring radical
36 surgery and adjuvant therapy that is associated with reduced overall survival. Yet compared to
37 other advanced malignancies, relatively little is known of the genomic landscape of metastatic
38 cSCC. We have previously reported the mutational signatures and mutational patterns of CCCTC-
39 binding factor (CTCF) regions in metastatic cSCC. However, many other genomic components
40 (indel signatures, non-coding drivers, and structural variants) of metastatic cSCC have not been
41 reported. To this end, we performed whole genome sequencing on lymph node metastases and
42 blood DNA from 25 cSCC patients with regional metastases of the head and neck. We designed a
43 multifaceted computational analysis at the whole genome level to provide a more comprehensive
44 perspective of the genomic landscape of metastatic cSCC.

45
46 In the noncoding genome, 3'UTR regions of *EVC* (48% of specimens), *PPP1RIA* (48% of
47 specimens) and *ABCA4* (20% of specimens) along with the tumor-suppressing lncRNA
48 LINC01003 (64% of specimens) were significantly functionally altered (Q-value < 0.05) and
49 represent potential noncoding biomarkers of cSCC. Recurrent copy number loss in the tumor
50 suppressor gene *PTPRD* was observed. Gene amplification was much less frequent and few genes
51 were recurrently amplified. Single nucleotide variants driver analyses from 3 tools confirmed *TP53*
52 and *CDKN2A* as recurrently mutated genes but also identified *C9* as potential novel driver in this
53 disease. Further, indel signature analysis highlighted the dominance of ID signature 13 (ID13)
54 followed by ID8 and ID9. ID 9 has previously been shown to have no association with skin
55 melanoma, unlike ID 13 and 8, suggesting a novel pattern of indel variation in metastatic cSCC.

56 The enrichment analysis of various genetically altered candidates shows enrichment of 'TGF-beta
57 regulation of extracellular matrix' and 'Cell cycle G1 to S check points'. These enriched terms are
58 associated with genetic instability, cell proliferation, and migration providing mechanisms of
59 genomic drivers of metastatic cSCC.

60 **INTRODUCTION**

61 Cutaneous squamous cell carcinoma (cSCC) is the second most common malignancy, after basal
62 cell carcinoma (BCC), affecting up to 1 000 000 people in the United States (US) annually [1] . In
63 time, and as a result of the ageing population and changing ratios of BCC/cSCC, the mortality rate
64 of cSCC is likely to exceed that of melanoma [2]. Although primary cSCC is common, metastasis
65 only occurs in 2-5% of cSCC [3-5]. cSCC arising in the head and neck generally show a predictable
66 pattern of spread, predominantly metastasizing to the intraparotid, level II (upper jugular) and
67 perifacial lymph nodes [4]. cSCC that have metastasized to regional lymph nodes are associated
68 with a worse prognosis [6], with modest progress made in the management of regionally advanced
69 disease over the last 15 years. Most patients with regional metastases from cSCC of the head and
70 neck are managed with a multimodality approach, which usually involves surgery (parotidectomy
71 and neck dissection) and adjuvant external beam radiotherapy depending on the site and stage at
72 the time of diagnosis [7-9]. More recently immunotherapy has attracted great interest as a potential
73 alternative for unresectable or distant metastatic disease [10, 11].

74
75 Despite the very high incidence, relatively little is known regarding the genomic landscape of
76 metastatic cSCC. We have previously described the genomic mutational burden, mutational
77 signatures, and mutations in CCCTC-binding factor regions using whole genome sequencing
78 (WGS) data from 15 cSCC metastases [12]. However, the majority of studies to date have reported

79 on somatic variation in primary cSCC [13-16] and/or cSCC metastases [16-20], using whole
80 exome sequencing (WES) and/or targeted next generation sequencing, which by definition
81 focusses on the coding genome. Thus, the extent of analysis of non-coding (including regulatory)
82 regions of the genome is limited and varies across studies. Pickering et al [20], the only study
83 employing WES, and incorporating 32 primary and only 7 metastatic samples, did not include
84 regulatory or non-exome regions analysis. Both Li et. al [18] (29 lymph node metastatic formalin
85 fixed paraffin embedded (FFPE) samples) and Zehir et. al [17] (MSK-IMPACT) (28 primary and
86 27 metastatic FFPE samples) used targeted NGS, with limited non-coding analysis. Zehir et al [17]
87 specifically included the *TERT* promoter in their targeted panels but otherwise included no
88 regulatory elements. Yilmaz et al. [16] performed WES and/or targeted NGS on 18 metastatic and
89 10 primary FFPE cSCC samples and reported coding gene drivers based purely on mutational
90 frequencies, without adjusting for gene length or covariates. Additional functional driver
91 predictions analysis would be required to confidently call genes as drivers [21]. Furthermore, FFPE
92 processing has well-known impacts on the quality of DNA for sequencing analyses [22] and it is
93 important to note that for most of the metastatic studies samples are collected using FFPE. Li et al
94 [18] similarly did not include regulatory or non-coding variant analysis. Furthermore, none of these
95 studies addressed variation in either 5' or 3' untranslated regions (UTR) or other non-coding
96 elements such as promoters (other than *TERT* promoter) or long non-coding RNAs. Sequence
97 variants occurring within these functional non-coding elements are important as they have the
98 potential to alter gene expression. For example, lncRNA are thought to influence expression of
99 proteins by pre- and post-translational influences on DNA/RNA and proteins, chromatin function,
100 miRNA activity and signaling pathways by an array of mechanisms [23, 24]. 3'UTRs regulate
101 crucial aspects of post-transcriptional gene regulation [25]. Mutations in these regions can

102 deregulate gene expression by disrupting miRNA-mRNA interactions, which in both tumor
103 suppressor genes and oncogenes can drive cancer progression [26, 27]. This variation in so called
104 *cis-elements* can also impact gene expression by altering translation initiation in cancer [28].

105
106 Given the shortcomings associated with WES and NGS analyses of complex genomes, in the
107 current report we have performed WGS on 25 metastatic cSCC samples and applied a detailed,
108 multifaceted computational analysis at the whole genome level to provide a comprehensive
109 understanding of the genomic landscape of metastatic cSCC. This included processing of WGS
110 data for somatic variations in both coding and non-coding regions, and indel signatures, apart from
111 structural variants and copy number alterations analyses. For non-coding genomic regions, we
112 have focussed on UTRs, lncRNA and promoters regions as these represent non-coding regions that
113 are most accessible to interrogation in high mutational burden tumours using currently available
114 tools.

115

116 **MATERIALS AND METHODS**

117 **Study population, sample collection and processing**

118 This study was undertaken with Institutional Human Research Ethics approval (UOW/ISLHD
119 HREC14/397). Thirty-two patients with resectable metastatic cSCC (28 from males and 4 from
120 females) were identified by the treating surgeons preoperatively. In addition to whole blood (for
121 germline DNA), sections of fresh tumor from nodal metastases were collected during surgery and
122 immediately snap frozen. These sections were used for both DNA/RNA extraction (Qiagen
123 AllPrep, Qiagen, Hilden, Germany) and for cellularity estimates. Only samples with > 30% tumor
124 (range 35-95%) proceeded to DNA quality control (QC). QC comprised spectrophotometry

125 (Nanodrop 2000 ThermoFisher Scientific Inc), gel-electrophoresis and SNP array. Of the 32
126 samples sequenced, 25 passed QC (96% from males) (Table 1). The remaining 7 samples had
127 insufficient clonal tumor content (median variant reads ≤ 5 or median VAF < 0.1) or had an
128 extreme GC bias as determined by PURPLE [29]. Briefly, if more than 220 copy number segments
129 were unsupported by a corresponding structural variants at either end, the sample was flagged as
130 Fail-Segment. The mean sequencing coverage of the 25 samples was $94.56\times$ (range: 64-143) for
131 tumor and $41.08\times$ (range: 30-56) for blood.

132 **Variant calling and functional significance of SNVs and indels**

133 FASTQ reads were aligned to reference genome GRChr38 using BWA-kit version 0.7.17 (BWA-
134 MEM read aligner) (for details refer to [https://github.com/Sydney-Informatics-Hub/Fastq-to-](https://github.com/Sydney-Informatics-Hub/Fastq-to-BAM)
135 [BAM](https://github.com/Sydney-Informatics-Hub/Fastq-to-BAM)). The Genome Analysis Tool Kit (GATK) 4.1.2.0 and its BaseRecalibrator tool was used to
136 refine the read alignment. Single nucleotide polymorphisms (SNPs) and insertion-deletion (indel)
137 variants were called by implementing GATK's Best Practices Workflow. These pipelines use
138 HaplotypeCaller for germline short variant discovery and Mutech2 caller for somatic short variant
139 discovery for SNVs and Indels (for details refer to [https://github.com/Sydney-Informatics-](https://github.com/Sydney-Informatics-Hub/Somatic-ShortV)
140 [Hub/Somatic-ShortV](https://github.com/Sydney-Informatics-Hub/Somatic-ShortV)). Furthermore, variants effect prediction and annotations were completed
141 using OpenCravat platform [30]. Mutation Annotation Format (MAF) files were generated based
142 with Variant Effect Predictor annotations. Three different methods for driver discovery were then
143 used; OncodriveFML[31], MutSigCV [21] and dNdScv [32].

144

145 OncodriveFML predicts the functional significance of both coding and non-coding variants as it
146 is one of the few tools designed for non-coding genomic analysis [31]. It first determines the
147 functional impact of the observed somatic mutations using Combined Annotation Dependent

148 Depletion (CADD) for specified genomic elements (UTR, promotor, coding regions) across the
149 cohort. Later, for the statistical significance, it compares the average functional impact score of
150 the observed mutations in the element with the average functional impact scores of a similar
151 number of the random mutational set. The CADD score provides a priority for identifying
152 mutations with functional, deleterious, and pathogenic impacts. These scores are calculated by
153 combining the information from multiple annotations into a single metric.

154

155 MutSigCV identifies genes that are mutated more often than expected by chance and reduces the
156 number of false positives in the generated list of significant genes, which is especially useful for
157 tumors, such as metastatic cSCC, with high mutation rates [21]. This is achieved by incorporating
158 various types of information such as patient-specific mutation frequencies and mutation spectra,
159 gene-specific mutation rates, expression levels and replication times.

160

161 dNdScv is designed to test for positive and negative selection in cancer genomes [32]. As UV-
162 induced cancer genomes such as cSCC can affect the accuracy of the dNdScv model we carefully
163 monitored the annotation of CC>TT changes (sometimes reported as C>T changes). Results report
164 significance for missense and truncating mutations, as well as indels as global p-values. Genes that
165 were falsely flagged as significant with negative selection were not considered for this analysis.

166

167 For downstream analysis, genes predicted to be driver genes by at least two of these tools were
168 considered. Firstly, genes with significance p-values <0.005 were filtered from each of the 3 tools,
169 and shared genes determined using a Venn diagram. We then compared the functional impact of
170 SNVs in these selected driver genes to previously reported primary and metastatic cSCC data [17,

171 18, 20, 33] available on cBioportal [34]. This included 92 samples of nodal metastatic cSCC
172 (WES= 10, targeted NGS = 82) and 88 samples of primary cSCC (WES=32, targeted NGS=56).

173 **Copy Number Variation**

174 Copy number alterations in the 25 metastatic genomes was derived using PURity & PLoidy
175 Estimator (PURPLE) [29], which estimates copy number and purity of tumor sample by using
176 read depth ratio from COBALT and tumor B-allele frequency (BAF) from AMBER. The pipeline
177 is available at github of HMF Tools (<https://github.com/hartwigmedical/hmftools>). Driver genes
178 with significant amplifications and deletions were then identified using PURPLE driver copy
179 number outputs. For driver genes, PURPLE searches for genes with high level amplification
180 (minimum Exonic Copy number $> 3 * \text{sample ploidy}$) and deletion (minimum exonic copy number
181 < 0.5) and then uses iteration to establish the most significant focal peaks.

182
183 GRIDSS2 and its companion interpreter tool LINX were employed for somatic structural variant
184 analysis and Gene fusion [35]. COSMIC3 based SNVs and Indels signatures from the whole
185 genome were built using MutationalPatterns [36] software, respectively.

186
187 The driver gene candidates obtained from various genetic alteration analyses such as copy number
188 variation drivers, somatic variant drivers, and other non-coding drivers were combined for
189 enrichment analysis. In the case of copy number gain/loss, we selected only those genes affected
190 in $>20\%$ of the samples in our cohort. Using the Enrichr web application [37] we determined the
191 involvement of the candidate driver genes in various cellular components of the cells, biological
192 pathways and predicted miRNA and drug targets.

193 **RESULTS**

194 **Patient characteristics and clinicopathologic data**

195 Twenty-five metastatic cSCC samples from lymph nodes in the head and neck region were
196 collected between 2015 and 2019 that passed WGS QC criteria for analysis (Table 1). The median
197 age of patients was 69 (range 30-87) and 24/25 (96%) were male. While this sex disparity is a
198 limitation of our study in that potential sex differences may have been missed, it is in keeping with
199 the disease burden seen in our practice in NSW, Australia, particularly for advanced and metastatic
200 cSCC (Ashford et al., manuscript under review). This is in keeping with findings that age, male
201 sex and immunosuppression are among the risk factors for metastasis [38]. Two patients were
202 immunocompromised; one patient was on long-term azathioprine for rheumatoid arthritis and the
203 other was on a combination of cyclophosphamide and tacrolimus following solid organ
204 transplantation.

205

206 The location of the index primary lesion was known in 11 patients (Table 1). Nodal metastases
207 were isolated from the neck in 13 patients and in the parotid in 12 patients. The majority of patients
208 had either moderately differentiated (n = 8) or poorly differentiated (n = 12) cSCC, with evidence
209 of extranodal extension found in 20/25 (80%) nodal samples.

210 **Tumor mutational burden (TMB)**

211 Based on whole genome level calculations, the average TMB for SNVs and Indels across the 25
212 cases was 238.7 mutations per megabase (range 32.52 to 995.66 mutations/Mb) and 2.25
213 indel/megabase (range 0.63 to 5.9 mutations/Mb), respectively (Figure 1A, 1B; Supplementary
214 Table 1) with the majority of somatic variants occurring in the non-coding regions as expected
215 [12]. The only female tumor in this cohort had the second highest TMB at 499 mutations/Mb.

216 There was no correlation between age, differentiation, nodal stage or extracapsular spread of the
217 metastasis and TMB.

218 **Mutational signatures**

219 We performed mutational signature analyses of the 25 genomes based on COSMIC V.3.2
220 (<https://cancer.sanger.ac.uk/signatures/>). Signatures are designated as single base substitution
221 (SBS), or small insertion and deletion (ID) signatures. SBS signatures 7a and 7b were the most
222 prevalent (Figure 1C; Supplementary Table 2) in keeping with a UV association in metastatic
223 cSCC as we previously reported in a smaller cohort using COSMIC V2 [12]. Substantial
224 representation of SBS7c was also seen. SBS32 and SBS7d were observed in one sample. Indel
225 signature analysis showed that ID8, 9 and 13 dominated over others (Figure 1D; Supplementary
226 Table 2).

227 **Short variants**

228 *Coding Short Variants*

229 The overwhelming majority of coding SNVs were missense mutations, followed by nonsense
230 mutation, which represented less than 5% of variants (Figure 2A). Figure 2B shows various DNA
231 sequence alterations, including single, double, and triple nucleotide variants as well as insertion
232 and deletion (Supplementary Data 1). Over 80% of SNVs were C>T (Figure 2C, 2D). This is
233 consistent with the dominant effect of UV radiation on pyrimidine bases and the UV signature
234 referred to above and is independent of the degree of differentiation or any other clinicopathologic
235 feature. Genes predicted to be driver genes via OncoDriveFML include *TP53*, *CDKN2A* and
236 *ZNF730* having Q-values <0.1 (Figure 2E). MutSigCV and dNdScv analyses also found *TP53* and
237 *CDKN2A* as the most significant mutated driver genes in our cohort (Supplementary Table 3).
238 Genes that were predicted to be driver genes (P-value < 0.005) by at least two tools were

239 considered for downstream analyses (Figure 2F). This resulted in 12 genes; *TP53*, *CDKN2A*, *C9*,
240 *C9orf131*, *SLC22A6*, *KHDRBS2*, *COLEC12*, *LINGO2*, *CDHR5*, *ZNF442*, *PRLR*, and *DHRS4*. Of
241 this list *TP53*, *CDKN2A* and *C9* were shared as significant by all 3 tools. Interrogation of the
242 cBioPortal dataset for cSCC (metastatic = 92 and primary=88 cases) [17, 18, 20] with short variant
243 analysis (Supplementary Figure 1) revealed recurrent mutations in *TP53*, *CDKN2A*, but also *C9*,
244 *COLEC12* and *SLC22A6*. Not all genes identified as high impact and recurrent variants in our
245 cohort were included in these targeted studies, which underscores the deficiencies of targeted
246 analyses in discovery projects.

247 The only sample with no mutation in *TP53* was CSCC_0009 (Figure 2G). The TMB of this sample
248 was 122/Mb, or 51% of the average across the cohort. Five samples without *CDKN2A* mutations
249 averaged a TMB of 470/Mb, or 201% of the average for the cohort.

250 *Variation in non-coding regulatory regions*

251 The 3'UTRs that potentially play an important role in metastatic cSCC were discovered using
252 OncodriveFML. SNVs within the 3'UTR region of *EVC*, *PPP1RIA*, *ABCA4*, and *LUM* showed
253 significantly higher observed functional impact than the expected functional impact (Q-value
254 <0.03) (Figure 3A, Supplementary Table 3). We observed variation within the 3'UTR of both *EVC*
255 and *PPP1RIA* in 48% of samples with a Q-value of 0.011 and 0.022, respectively (Figure 3B;
256 Supplementary Table 4). The unique *PPP1RIA* variant with cDNA change of c.*491C>T
257 [Chr12:54579896 (G to A)] was found in 5 samples (Supplementary Figure 2).

258

259 There are many reported limitations in the analysis and interpretation of 5'UTRs and promoters
260 for high mutational burden tumors [39-41], a finding we also observed (Supplementary Figure 3).

261 Currently no robust methodology exists to analyze these regions with confidence in cSCC thus
262 analyses of 5'UTRs and promoter regions were not investigated further.

263
264 lncRNAs likely to have a potential impact on tumorigenesis were also predicted using
265 OncodriveFML. Four lncRNAs were significantly ($q < 0.05$) biased towards high-impact
266 mutations i.e *LINC01474* and *LINC01003*, *RP4-597N16.4*, and *RP11-61J19.4* (Figure 3C;
267 Supplementary Table 3). Among these *LINC01474* and *LINC01003*, showed a high statistical
268 significance Q-value of 0.0158. lncRNA *LINC01003* was altered in 64% of the cohort. Other
269 recurrently mutated lncRNAs in our cohort was *RP11-61J19.4* (48% of samples) (Figure 3D;
270 Supplementary Table 4).

271 **Structural and copy number variation**

272 The extent of chromosomal copy number gain and loss was averaged across the genome for all 25
273 tumor samples (Figure 4A; Supplementary Table 5). Chr5p and 8q were the most frequently
274 amplified regions, with 18q being the region with the most recurrent deletion. At sample level
275 (Figure 4B), there were chromosome arm gains in Chromosome 7 and 5p in the majority of the
276 samples and losses in 8p, 18q and 21q. Recurrent gain of 7, 8q, 5p and loss of 8p, 18, 21 was also
277 previously reported by Pickering et al [20].

278
279 Structural variation analysis revealed that cSCC metastases are characterized by various complex,
280 deleted, and unbalanced translocation events. Table 2 provides the summary of various structural
281 events observed. Deletion and complex structural variants are common in cSCC; however,
282 unbalanced translocation and other structural events were also observed (Table 2). The detailed
283 effects of these structural events for putative oncogenes and tumor suppressor genes (TSG) are
284 described in Table 3. Amplification events are linked to complex structural variants. Potential

285 oncogene/TSG driver amplification and deletion were predicted by the PURPLE-GRIDSS-LINX
286 pipeline, as reported in Table 3. Recurrent gene deletions were more common than gene
287 amplifications. The most frequently deleted gene was *PTPRD* (Chr9p, 24% of samples). *PTPRD*
288 deletion is already reported in primary and metastatic CSCC [42, 43]. Deletion of *PTPRD* (n=6)
289 and *CDKN2A* (Chr9p) (n=1) did not co-occur in our cohort (Table 3), although *PTPRD* loss and
290 significant mutation of *CDKN2A* co-occurred in 6 samples (CSCC_9, 11, 12, 133, 132 and 134)
291 (Table 3 and Figure 2G). Deep deletion of *CDKN2A* was reported in only 2/92 cases available on
292 cBioPortal (Supplementary Figure 1).

293
294 Loss of heterozygosity (LOH) was found at the focal, arm, chromosome, telomere, and centromere
295 levels. The most common LOH events were that at the chromosome and arm level with these
296 events concentrated to *PTPRD* locus (Table 3). No recurrent events for other genes among were
297 observed (Table 3). Various examples of *PTPRD* structural events are reported in Supplementary
298 Figure 4. A few other examples of the unbalanced translocation and complex structural variants
299 are shown in Supplementary Figure 5.

300
301 The most frequently amplified genes (2/25, 8%) were *CALR*, *CCND1* and *FGF3* (Table 3).
302 Interestingly *EGFR* was amplified in only one sample. Amplification of *CCND1* and *FGF3* co-
303 occurred in 2 samples (CSCC_0134 and CSCC_0132). *CCND1* and *FGF3* are next to each other
304 on the chromosome. These 2 cases had extensive nodal involvement (>50% of lymph nodes
305 harboring tumor).

306

307 Despite this widespread genomic instability, only 2 coding-coding gene fusions were observed in
308 our cohort. The first was between *STRN* and *DLG2* in sample CSCC_0009 (*STRN*: Exon 1
309 ENST00000263918 - *DLG2* Exon 7 ENST00000376104). *STRN* encodes a calcium-dependent
310 calmodulin-binding protein [44]. *DLG2* plays a role in pain signalling and deletion is seen in both
311 human and canine osteosarcoma [45]. We noted above that CSCC_0009 is the only sample without
312 *TP53* mutations. CSCC_0009 came from a patient who had undergone liver transplantation and
313 was on immunosuppressive therapy. The primary tumor that gave rise to this metastasis showed
314 perineural involvement, which was also present in the metastatic deposit. The second gene fusion
315 was between *NTRK2* and *HEBP2* in CSCC_0011-M1. This seems to be caused by unbalanced
316 translocation event (**Supplementary Figure 5.B**).

317 **Enrichment analysis**

318 Gene enrichment analysis was performed using the 21 genetically altered candidates identified
319 above as significant/candidate driver genes, i.e., *TP53*, *CDKN2A*, *C9*, *KHDRBS2*, *SLC22A6*,
320 *COLEC12*, *LINGO2*, *CDHR5*, *ZNF442*, *C9orf131*, *PRLR*, *DHRS4*, *PPP1R1A*, *EVC*, *LUM*,
321 *ABCA4*, *LINC01003*, *LINC01474* (*RP11-151D14.1*), *RP4-597N16.4*, *RP11-61J19.4*, and *PTPRD*.
322 The top significant pathway enrichment terms (Bio Planet 2019 [46]) are shown in Figure 5A.
323 Most of the significant Bioplanet enriched terms come from *TP53* and *CDKN2A*, such as TP53
324 network, tumor suppressor ARF, CTCF pathway and cell cycle (G1/S checkpoint). However,
325 *CDKN2A*, *LUM*, *CDHR5* and *COLEC12* contribute to important cancer-related enrichment
326 pathways, such as ‘TGF-beta regulation of extracellular matrix.’ Full details of these enrichment
327 analyses are available in Supplementary Table 6.
328 The Jensen diseases enrichment tool identified skin cancer with highest significance (Figure 5B)
329 with Jensen compartment-based enrichment analysis showing that most of these genes belongs to

330 the extracellular compartment (Figure 5C). Other ontology enrichment analysis (MGI Mammalian
331 Phenotype Level 4 2021; Supplementary Table 6) showed enrichment of increased fibroblast
332 proliferation MP:0011703 where *CDKN2A*, *TP53* and *LUM* alteration are the main contributors.
333 We also predicted the miRNA targets for these driver candidates (Figure 5D). *hsa-miR-331-5p*
334 was predicted to interact with 6 driver gene candidates, including *TP53* and *C9*. For this prediction,
335 enricher platform use TargetScan miRNA database [47]. At the same time, *hsa-miR-1181* was one
336 of the most significantly enriched miRNAs for these driver candidates, however can target only 2
337 driver genes.

338 **DISCUSSION**

339 This is the largest study to employ WGS to assess the mutational landscape of metastatic cSCC
340 and demonstrates the breadth of somatic variation across non-coding and coding regions.
341 Furthermore, we updated and expanded the understanding of UV-mutational signature patterns in
342 metastatic cSCC [12], including the identification of novel Indel (ID) signature patterns. This
343 highlights for the first time the nature and depth of variation within regulatory regions, with special
344 attention devoted to UTR, and lncRNA. Additionally, we reported various structural events at
345 whole genome scale for this diseases and also compared driver genes and SNVs to previous
346 WES/targeted NGS studies on metastasis cSCC.

347
348 At 238 mutations/Mb (Median of 166.99 mutations/Mb) (at whole genome scale), the rate of TMB
349 within metastatic cSCC is substantially higher than other cancers known to have high mutational
350 burden, including melanoma (49 mutations/Mb) [48]. This finding is in keeping with Pickering et
351 al [20] who found a median of 61.2 mutations/Mb from their WES of high risk primary (n= 32)

352 and metastatic (n =7) cSCC being 4 times that of melanoma. The high TMB was associated with
353 substantial structural variation, without recurrent gene fusions.

354

355 Alexandrov et al [49] detailed patterns of mutational signatures in 23829 tumor samples (1965
356 WGS) from the Pan Cancer Analysis of Whole Genomes (PCAWG) datasets including 17 small
357 ID signatures, expanded to 18 in COSMIC version 3.2 (<https://cancer.sanger.ac.uk>) [50]. However,
358 no cutaneous SCC (primary or metastatic) are included in this dataset. We identified the
359 predominance of ID signatures 8, 9 and 13 (100% of samples effected) in our 25 metastatic cSCC
360 samples. ID 8 is thought to be both related to double strand DNA break repair dysfunction and to
361 age related changes. Melanoma is the only other cancer type reported to have a predominant ID
362 13 signature [49]. Our data also provides evidence of concomitance of ID 13 with SBS 7a and 7b
363 (Figure 1C, 1D and Supplementary Table 2) in keeping with a UV-mediated mechanism for this
364 signature. While we found ID 9 to be a dominant indel signature in cSCC it is rare in melanoma
365 (2/104) but predominant in soft tissue sarcoma [49]. The mechanism of ID 9 is unclear but this
366 departure from what is found in melanoma clearly shows some point of difference in these UV-
367 induced skin cancers. When comparing the TMB associated with ID 9 signature among different
368 cancers, the dominance in cSCC is clearly visible (Figure 6).

369

370 We identified substantial somatic variation within the 3'UTR region of *EVC*, *LUM* and *PPP1RIA*.
371 *EVC* effects ciliary Hedgehog (Hh) regulation. Aberrant overexpression of *EVC* (and upregulation
372 of Hh) has been reported in adult T-cell leukaemia as a result of epigenetic modulation [51]. The
373 expression of *EVC* is reduced in nodal deposits of metastatic breast cancer compared with primary
374 breast cancer suggesting a role in the metastatic process [52]. *PPP1RIA* is a protein phosphatase

375 inhibitor which appears to have a variable but significant role in the metastatic process. For
376 example, it is overexpressed in Ewing Sarcoma, and has been proposed as a driver of metastasis
377 [53]. Conversely, levels of *PPP1R1A* were reduced in breast cancer when compared to adjacent
378 non-diseased breast tissue [54]. Within our cohort, we observed a unique recurrent missense
379 mutation in the 3'UTR of *PPP1R1A* in 5 samples.

380
381 *LINC01003* was the most mutated lncRNA in our cohort (64% of samples). In multiple myeloma,
382 *LINC01003* behaves as a tumor suppressor genomic element. Up-regulation suppresses multiple
383 myeloma by repressing cell viability and adhesion and promoting apoptosis. This effect is via its
384 sponge effect on miR-33a-5p and its target *PIMI* [55].

385
386 As has been frequently reported for cSCC [5] (Supplementary Figure 1), *TP53* and *CDKN2A* were
387 also the most recurrently altered genes in our cohort. Loss of function mutations within *TP53* and
388 *CDKN2A* are well known to adversely impact cell cycle pathway control and DNA repair
389 mechanisms. Kilnakis et al [56] describe a pattern of *TP53* mutation that differed between primary
390 and metastatic disease in head and neck (mucosal) SCC. They found an overall lower rate of
391 mutations in metastatic tumors, but a higher concentration of missense mutations in the DNA
392 binding regions of the gene. However, Yilmaz et al [16] reported a significantly higher *TP53*
393 mutation frequency in metastatic (85%) compared to primary tumors (corrected p-value <0.002).
394 Additionally, they found a higher TMB with *TP53* mutation, but a worse response to
395 immunotherapy. Burtneess et al [57] reported that the extent of TMB in HPV-negative HNSCC is
396 associated with loss of function mutations in both *TP53* and *CDKN2A* .

397 Of note in our study was the absence of significant or recurrent SNVs affecting *NOTCH1/2*. Inman
398 et al [14] compared well differentiated to moderately and poorly differentiated primary cSCC and
399 identified *NOTCH1*, *NOTCH2*, *TP53* and *CDKN2A* as the most commonly mutated genes, with
400 *ATPIA1*, *HERC6*, *MAPK1P1L*, *GRHL2*, *TRAPPC9*, *FLNB* and *MAP3K9* identified as common
401 early events in primary cSCC. Within this group, *GRHL2* was associated with less well
402 differentiated tumors including those with a worse prognosis. In our cohort, only a single splice
403 variant in *GRHL2* was identified, suggesting its role in metastatic disease is limited.

404 *C9*, (encodes complement component 9, *C9*) was also identified as a potential driver gene by 3
405 driver identification tools, with SNVs identified in 52% of the samples in our cohort. *C9* is a part
406 of the membrane attack complex (MAC) and has been shown to modulate cellular behavior in the
407 tumor microenvironment (TME) [58]. Since the TME plays a crucial role in tumorigenesis,
408 progression, metastasis, and recurrence, *C9* might have significant potential in cSCC progression
409 to metastasis. Various other components of the complement system have been linked to cSCC
410 progression and immunosuppression and implicated as potential therapeutic targets [59-61]. With
411 respect to *C9* specifically, it appears to be recurrently mutated in cSCC specimens (31% in primary
412 and 10% in metastatic cSCC) as identified in the cBioPortal database (Supplementary Figure 1).
413 and high expression levels have been proposed as a potential biomarker for the detection of gastric
414 cancers [62] [63]. Further, the restrained expression of *C9* in tumor-associated macrophages
415 promotes non-small cell lung cancer progression [64].

416

417 Apart from *TP53*, *CDKN2A* and *C9*, we identified 9 other potential driver genes with the most
418 recurrently mutated gene being *KHDRBS2* (48% of cohort) with various impacts, including stop
419 gained, complex and synonymous types apart from missense variant across the cohort. In the

420 cBioPortal database, this gene is mutated in 20% of metastatic cSCC specimens (Supplementary
421 Figure 1), suggesting it is a reasonably recurrently mutated gene in this disease.

422 Comparison of mutational frequency of primary and metastatic on the cBioPortal data suggests
423 the potential of *COLEC12* (primary=25%; metastatic=60%) and *SLC22A6* (primary=16%;
424 metastatic=30%) as a driver in metastatic cSCC (Supplementary Figure 1). Both *COLEC12* and
425 *SLC33A6* are mutated in 44% of the samples in our cohort, and many of them are high impact
426 SNVs. *COLEC12* is involved in leukocyte recruitment and cancer metastasis [65], and regulates
427 the apoptosis of osteosarcoma [65]. Moreover, *COLEC12* is a potential biomarker of anaplastic
428 thyroid cancer (ATC) [66]. In one cancerous study of gastric stromal cells (GSCs), the role of
429 *COLEC12* is found in mediating the crosstalk between GSCs and dendritic cells (DCs) [67]. On
430 the other hand, *SLC22A6* is known as an organic anion transporter 1 (*OATI*). Expression and
431 function alterations of *OATI* play an essential role in therapeutic efficacy and the toxicity of many
432 drugs. Such as for anti-cancer drugs methotrexate, Bleomycin, and Cisplatin-related toxicity [68-
433 70]. *OATI* variation associated with cardiotoxicity in pediatric acute lymphoblastic leukemia and
434 osteosarcoma [71]. Furthermore, *OATI* role in Breast cancer metastasis has been reported [72].
435 Important cancer-related roles of the other potential cSCC drivers are reported in Supplementary
436 Table 7.

437
438 Loss of *PTPRD* was the most prominent copy number alteration in our 25 samples. *PTPRD*
439 encodes protein tyrosine phosphatase receptor D, which belongs to a family of receptors whose
440 action oppose that of the tyrosine kinases, which are central to cell growth and differentiation and
441 oncogenic transformation. Large scale genomic events impacting *CDKN2A* can also affect *PTPRD*
442 due to their proximity on chr9 [73]. In head and neck SCC, *PTPRD* inactivation significantly

443 increases *STAT3* hyperactivation, which was associated with decreased survival and resistance to
444 EGFR-targeted therapy [74]. *PTPRD* has been implicated as a tumor suppressor in several cancers
445 with inactivating somatic variants found in >50% of GBM and between 10-20% of head and neck
446 mucosal SCC (HNSCC) [75]. Lambert et al. [43] described deletions of *PTPRD* in 37% of
447 metastatic primary cSCC and metastases. In addition, some of their cases also displayed a variant
448 in the minor allele concordant with the deletion leading to a LOH event. It is thus possible that
449 *PTPRD* plays a tumor suppressor role in preventing metastatic cSCC.

450
451 There were no recurrently amplified genes except for *CALR*, *CCND1* and *FGF3* which were each
452 only amplified in 2/25 samples (Table 3). *CALR* encodes a ubiquitous endoplasmic reticulum
453 bound calcium receptor [76]. Cellular stress can move *CALR* fragments to the plasma membrane
454 from the ER and influence immune recognition of cancer cells. Recent analysis of *CALR* fragments
455 in myeloproliferative disease suggest an immunosuppressive influence of extracellular *CALR* [77].
456 Cyclin D1 (*CCND1*) amplification is associated with nodal metastasis and worse survival in oral
457 SCC [78]. In a review of *CCND1* copy number variation in metastatic non-cutaneous melanoma,
458 amplification was prominent in those patients whose disease did not respond to immune
459 checkpoint inhibition [79]. *FGF3* amplification is more common in metastatic breast cancer than
460 primary tumors [80]. Targetable *FGF3* amplification was associated with a poorer prognosis and
461 lung metastasis in hepatocellular carcinoma [81]. This amplification was seen in only 2% of total
462 HCC but was most common in those cancers showing rapid response to sorafenib.

463
464 With respect to enrichment of driver gene alterations observed in our samples, dysregulation of
465 the cell cycle pathway appears to be the central genomic theme of metastatic cSCC supported

466 mainly by *TP53* and *CDKN2A*. *CDKN2A* encodes the CDK inhibitor p16^{INK4a}. This inhibitor is an
467 important controller of the activity of CDKs and progression from G1 to mitosis in the cell cycle.
468 Inactivating mutations in *CDKN2A* with effects on p16^{INK4a} regulatory functions uncouple cell
469 cycle control to promote tumorigenesis [82]. Interaction between *CDKN2A* and *TP53* through
470 *MDM2* and its regulation by ARF (also encoded by *CDKN2A*) further disable cell cycle and
471 apoptotic pathways (GO: Molecular function enrichment shows MDM2/MDM4 family protein
472 binding).

473 The cellular process defined by the term “TGF beta regulation of extra cellular matrix” was also
474 significantly enriched showing a role for *LUM*, *CDHR5*, *COLEC12* and *CDKN2A* in this process
475 (Figure 5A). TGF-beta modulates the deposition of the extracellular matrix (ECM) and affects cell
476 proliferation, differentiation, and migration.

477 Finally, miR-331-5p shows promise as a potentiator of cSCC drivers. miR-331-5p down-
478 regulation contributes to chemotherapy resistance/relapse in leukemia [83] and it inhibits
479 proliferation by targeting PI3K/Akt and ERK1/2 pathways in colorectal cancer [84].

480 **CONCLUSION**

481 WGS provides insight into the unparalleled burden of mutation within metastatic cSCC, and our
482 study has provided a deeper understanding of the genomic complexity of this disease. The
483 functional impact of the varied and complex genetic alterations observed in metastatic cSCC
484 should be validated in the future in confirmatory studies comparing whole genomes of non-
485 metastatic primary tumours to metastatic tumours. This would significantly contribute to the
486 identification of biomarkers in primary cSCC for predicting metastasis.

487

488 **ACKNOWLEDGMENTS**

489 This work was funded by the Illawarra Cancer Carers, The Head and Neck Research Fund, Royal
490 Prince Alfred Institute of Academic Surgery, The Cancer Institute NSW translational program
491 grant, Chris O'Brien Lifehouse, National Health and Medical Research Council Project Grant
492 APP1181179 and Tour de Cure. Authors would like to acknowledge National Computational
493 Infrastructure (NCI-GADI) and Sydney Informatics Hub for computational services.

494

495 **CONFLICT OF INTEREST STATEMENT**

496 **The authors state no conflict of interest.**

497 **AUTHOR CONTRIBUTIONS STATEMENT**

498 AT performed the bioinformatics analyses and assisted in drafting the manuscript draft. BA
499 conceived the idea, assisted in bioinformatics analyses and drafted the manuscript. DS performed
500 bioinformatic analysis. MR assisted in drafting and editing the manuscript. BA and MR obtained
501 funding for the project. JM and RG collated clinical data. JP, EM completed tissue processing. JP,
502 EM, JC, RG, JL, SM reviewed and edited the manuscript.

503 **DATA AVAILABILITY STATEMENT**

504 The data files used for genomic analysis have been deposited at the European Genome-
505 Phenome Archive, which is hosted by the EMBL-European Bioinformatics Institute and the
506 Center for Genomic Regulation, under accession number EGAS00001003370

507

Table 1. Clinicopathologic data of the cohort of 25 patients with cSCC lymph node metastases.

Sample	Primary location	Metastasis location	Immuno-suppressive treatment
CSCC_0001	left lip	left neck	no
CSCC_0002	right ear	right parotid	no
CSCC_0003	unknown	right parotid	no
CSCC_0004	bilateral lip	bilateral neck	no
CSCC_0005	left forehead	left parotid	no
CSCC_0006	left cheek	left neck	azathioprine
CSCC_0007	unknown	left neck	no
CSCC_0009	bilateral forehead	right neck	cyclosporine A, tacrolimus
CSCC_0010	left scalp	left neck	no
CSCC_0011	unknown	right parotid	no
CSCC_0012	right nose	right neck	no
CSCC_0013	right pinna	right parotid	no
CSCC_0014	left cheek	left perifacial	no
CSCC_0022	scalp	left neck	no
CSCC_0024	lip	right neck	no
CSCC_0025	parotid	Parotid	no
CSCC_0066	Unknown	Parotid	no
CSCC_0124	Parotid	Parotid	no
CSCC_0125	parotid	parotid	no
CSCC_0126	left temple	left neck	no
CSCC_0130	unknown	left parotid	no
CSCC_0132	right ear	parotid/neck	no
CSCC_0133	unknown	parotid	no
CSCC_0134	unknown	right neck	no
CSCC_0135	unknown	right neck	no

Table 2: Summary of various event categories of structural variants. For more details, refer to Supplementary figures 4 and 5. Association can be noted between gain (Table 3) and complex SV events. The gene list was derived using LINX output. Only samples with events shown in Table.

Sample	SGL	Del	DUP	Complex	UNBAL_Trans	Pair.Other	INF
CSCC_0001	<i>SMAD4</i>	<i>SMAD4</i>					
CSCC_0002		<i>CDKN2A</i>					
CSCC_0005			<i>MYC</i>	<i>MYC</i>			
CSCC_0007				<i>CRLF2</i>			
CSCC_0009		<i>PTPRD</i>					
CSCC_0011		<i>PTPRD</i>		<i>CALR</i>	<i>HEBP2- NTRK2</i>		
CSCC_0012		<i>PTPRD</i>		<i>EGFR</i>		<i>PTPRD</i>	
CSCC_0013		<i>APC</i>					
CSCC_0014		<i>CREBBP</i>					<i>CREBBP</i>
CSCC_0025		<i>CDKN2C</i>			<i>PARD6G</i>		
CSCC_0066		<i>PTPN13</i>					
CSCC_0124		<i>NEGR1</i>				<i>NEGR1</i>	
CSCC_0132		<i>PTPRD</i>		<i>RAF1-FGF3-CCND1</i>			
CSCC_0133	<i>PTPRD</i>	<i>PTPRD</i>		<i>CALR-chr1-chr3-chr6-chr8-chr22</i>			
CSCC_0134				<i>MCL1, CCND1-FGF3-Chr17</i>			
CSCC_0135		<i>PTPRD</i>					

NBAL_TRANS -unbalanced translocation; **INF** = inferred breakend ; **DEL**=deletion; **DUP**=duplication; **SGL** =single breakend SV support

Table 3: List of reportable drivers (Likelihood Type Onco/TSG) genes. Types of drivers are: GAIN = amplification by SV; DEL= homozygous deletion; LOH = focal LOH; LOH_ARM = chromosome arm level LOH; LOH_CHR = chromosome level LOH; LOH_SV_TELo = LOH from SV to telomere; LOH_SV_CENTRO = LOH from SV to centromere. Only samples with events shown in Table.

Sample	DEL	GAIN	LOH_CHR	LOH_ARM	LOH	LOH_SV_TELo	LOH_SV_CENTRO
CSCC_0001	<i>SMAD4</i>					<i>SMAD4</i>	
CSCC_0002	<i>CDKN2A</i>						
CSCC_0003	<i>KDM6A</i>		<i>KDM6A</i>				
CSCC_0005		<i>MYC</i>					
CSCC_0007		<i>CRLF2</i>					
CSCC_0009	<i>PRPRD</i>			<i>PRPRD</i>			
CSCC_0011	<i>PRPRD</i>	<i>CALR</i>		<i>PRPRD</i>			
CSCC_0012	<i>PRPRD</i>	<i>EGFR</i>	<i>PPP2R3B, PUDP, STS,WWC3</i>		<i>PRPRD</i>		
CSCC_0013	<i>APC</i>			<i>APC</i>			
CSCC_0014	<i>CREBBP</i>					<i>CREBBP</i>	
CSCC_0025	<i>CDKN2C, PARD6G</i>		<i>PARD6G</i>	<i>CDKN2C</i>			
CSCC_0066	<i>PTPN13</i>		<i>PTPN13</i>				
CSCC_0124	<i>NEGR1</i>				<i>NEGR1</i>		
CSCC_0132	<i>PRPRD</i>	<i>RAF1,CCND1,FGF3</i>		<i>PRPRD</i>			
CSCC_0133	<i>PRPRD</i>	<i>CALR</i>					<i>PRPRD</i>
CSCC_0134		<i>MCL1,CCND1,FGF3</i>					
CSCC_0135	<i>PRPRD</i>			<i>PRPRD</i>			

FIGURES

Figure 1. Overview of tumor mutational burden and signatures (whole genome-based). (A, B) illustrate the indel and SNV mutational burden in each sample, respectively. (C, D) show Indel (ID) and SNV mutational signatures for each sample, respectively, obtained using COSMIC V3.2 database. Full details are available in Supplementary Table 2 (Tabs 2-4).




Figure 2. Overview of key coding mutations. (A) Variants classification, (B) variant types, (C) % transitions in all 25 samples and (D) % transitions for each sample. (E) Driver coding genes prediction results from OncoDriveFML tool. The plot shows the most significantly altered genes (in the plots above the red line Q-values are below 0.1). Q-values are corrected P-values using the Benjamini/Hochberg correction (F) Venn diagram showing the overlap of genes predicted to be driver genes (P-value < 0.005) by 3 different driver detection tools, i.e. OncoDriveFML, MutSigCV and dNdScv. (For details refer to Supplementary Table 3). For further analysis, genes predicted to be driver genes by at least 2 tools were considered. (G) Detailed sample-level information of the SNVs along with types of variants in the top altered genes (from Figure 2F).




Figure 4. Chromosomal and recurrent genetic copy number variation.(A) Combined chromosomal CNV across 25 metastatic cSCC samples at the chromosomal level. The X-axis represents the differences of mean minimum copy number (bands) and means of overall samples ploidy (after adjustment for purity). Refer to Supplementary Table 5. (B) Chromosomes arm loss and gain at the sample level (Red denotes a gain, and blue denotes a loss). Both arms of chromosomes 7 and 5p show gains. 8p, 18q, and 21q show loss. (A chromosome arm is defined to be deleted if at least half of its bases are one or more copies less than the sample ploidy. A chromosome arm is defined to be amplified if at least half of its bases are one or more copies more than the sample ploidy.). Also shown is a Circos plot obtained from the PURPLE pipeline for CSCC_0004 as a representative example that summarizes various information at the sample level.




Figure 5. Enrichment analysis results of genetically mutated genes (21 candidates). (A) GO-Cellular Component terms showing 8 significantly enriched terms (obtained from BioPlanet 2019). (B) and (C) showing most significant Jensen diseases and Jensen compartments enriched terms, respectively. (D) Computationally predicted targets of miRNAs (TargetScan miRNA 2017). The x-axis represents the significance of the term. For details, refer to Supplementary Table 6.





Figure 6. Comparison plot of ID9 mutations for various cancers. cSCC shows the highest ID9 mutations per Mb. The bottom x-axis represents the cancer types, and the upper x-axis shows the number of samples measured for specific cancer types. Y-axis indicates the number of mutations per Mb. Data for other cancers was obtained from ID9 signature details from COSMIC V3.2 and compared with cSCC data. cSCC data is calculated as ID9 signature score/3100 (Coverage for hg38 genome).



REFERENCES

1. Rogers, H.W., et al., *Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012*. JAMA dermatology, 2015. **151**(10): p. 1081-1086.
2. Waldman, A. and C. Schmults, *Cutaneous Squamous Cell Carcinoma*. Hematol Oncol Clin North Am, 2019. **33**(1): p. 1-12.
3. Venables, Z.C., et al., *Nationwide incidence of metastatic cutaneous squamous cell carcinoma in England*. JAMA dermatology, 2019. **155**(3): p. 298-306.
4. Forest, V.I., et al., *NIS3: a revised staging system for head and neck cutaneous squamous cell carcinoma with lymph node metastases: results of 2 Australian Cancer Centers*. Cancer: Interdisciplinary International Journal of the American Cancer Society, 2010. **116**(5): p. 1298-1304.
5. Ashford, B.G., et al., *Reviewing the genetic alterations in high-risk cutaneous squamous cell carcinoma: A search for prognostic markers and therapeutic targets*. Head Neck, 2017. **39**(7): p. 1462-1469.
6. Mooney, C.P., et al., *The significance of regional metastasis location in head and neck cutaneous squamous cell carcinoma*. Head Neck, 2021. **43**(9): p. 2705-2711.
7. Veness, M.J., *Treatment recommendations in patients diagnosed with high-risk cutaneous squamous cell carcinoma*. Australas Radiol, 2005. **49**(5): p. 365-76.
8. Garcia-Foncillas, J., et al., *Update on Management Recommendations for Advanced Cutaneous Squamous Cell Carcinoma*. Cancers (Basel), 2022. **14**(3).
9. Stanganelli, I., et al., *The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts*. Cancers (Basel), 2022. **14**(2).
10. Migden, M.R., et al., *PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma*. N Engl J Med, 2018. **379**(4): p. 341-351.
11. Aboul-Fettouh, N., et al., *Immunotherapy and Systemic Treatment of Cutaneous Squamous Cell Carcinoma*. Dermatol Pract Concept, 2021. **11**(Suppl 2): p. e2021169S.
12. Mueller, S.A., et al., *Mutational Patterns in Metastatic Cutaneous Squamous Cell Carcinoma*. J Invest Dermatol, 2019. **139**(7): p. 1449-1458 e1.
13. Zilberg, C., et al., *Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma*. Modern Pathology, 2018. **31**(2): p. 275-287.
14. Inman, G.J., et al., *The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature*. Nat Commun, 2018. **9**(1): p. 3667.
15. Al-Rohil, R.N., et al., *Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies*. Cancer, 2016. **122**(2): p. 249-57.
16. Yilmaz, A.S., et al., *Differential mutation frequencies in metastatic cutaneous squamous cell carcinomas versus primary tumors*. Cancer, 2017. **123**(7): p. 1184-1193.
17. Zehir, A., et al., *Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients*. Nature medicine, 2017. **23**(6): p. 703-713.
18. Li, Y.Y., et al., *Genomic analysis of metastatic cutaneous squamous cell carcinoma*. Clin Cancer Res, 2015. **21**(6): p. 1447-56.
19. Chang, D. and A.H. Shain, *The landscape of driver mutations in cutaneous squamous cell carcinoma*. NPJ Genom Med, 2021. **6**(1): p. 61.

20. Pickering, C.R., et al., *Mutational landscape of aggressive cutaneous squamous cell carcinoma*. Clin Cancer Res, 2014. **20**(24): p. 6582-92.
21. Lawrence, M.S., et al., *Mutational heterogeneity in cancer and the search for new cancer-associated genes*. Nature, 2013. **499**(7457): p. 214-218.
22. Hedegaard, J., et al., *Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue*. PLoS One, 2014. **9**(5): p. e98187.
23. Statello, L., et al., *Author Correction: Gene regulation by long non-coding RNAs and its biological functions*. Nat Rev Mol Cell Biol, 2021. **22**(2): p. 159.
24. Cesana, M., et al., *A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA*. Cell, 2011. **147**(2): p. 358-69.
25. Barrett, L.W., S. Fletcher, and S.D. Wilton, *Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements*. Cellular and molecular life sciences, 2012. **69**(21): p. 3613-3634.
26. Liu, W. and X. Wang, *Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data*. Genome Biol, 2019. **20**(1): p. 18.
27. Schuster, S.L. and A.C. Hsieh, *The Untranslated Regions of mRNAs in Cancer*. Trends Cancer, 2019. **5**(4): p. 245-262.
28. Kobayashi, H. and Y. Tomari, *RISC assembly: coordination between small RNAs and Argonaute proteins*. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms, 2016. **1859**(1): p. 71-81.
29. Priestley, P., et al., *Pan-cancer whole-genome analyses of metastatic solid tumours*. Nature, 2019. **575**(7781): p. 210-216.
30. Pagel, K.A., et al., *Integrated Informatics Analysis of Cancer-Related Variants*. JCO Clin Cancer Inform, 2020. **4**: p. 310-317.
31. Mularoni, L., et al., *OncodriveFML: a general framework to identify coding and non-coding regions with cancer driver mutations*. Genome Biol, 2016. **17**(1): p. 128.
32. Martincorena, I., et al., *Universal Patterns of Selection in Cancer and Somatic Tissues*. Cell, 2017. **171**(5): p. 1029-1041.e21.
33. Gao, J., et al., *Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal*. Sci Signal, 2013. **6**(269): p. p11.
34. Cerami, E., et al., *The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data*. Cancer Discov, 2012. **2**(5): p. 401-4.
35. Cameron, D.L., et al., *GRIDSS2: comprehensive characterisation of somatic structural variation using single breakend variants and structural variant phasing*. Genome Biol, 2021. **22**(1): p. 202.
36. Blokzijl, F., et al., *MutationalPatterns: comprehensive genome-wide analysis of mutational processes*. Genome medicine, 2018. **10**(1): p. 1-11.
37. Kuleshov, M.V., et al., *Enrichr: a comprehensive gene set enrichment analysis web server 2016 update*. Nucleic Acids Res, 2016. **44**(W1): p. W90-7.
38. Tokez, S., et al., *Cumulative incidence and disease-specific survival of metastatic cutaneous squamous cell carcinoma: a nationwide cancer registry study*. J Am Acad Dermatol, 2021.
39. Mao, P., et al., *ETS transcription factors induce a unique UV damage signature that drives recurrent mutagenesis in melanoma*. Nat Commun, 2018. **9**(1): p. 2626.
40. Perera, D., et al., *Differential DNA repair underlies mutation hotspots at active promoters in cancer genomes*. Nature, 2016. **532**(7598): p. 259-63.

41. Sabarinathan, R., et al., *Nucleotide excision repair is impaired by binding of transcription factors to DNA*. Nature, 2016. **532**(7598): p. 264-7.
42. Purdie, K.J., et al., *Single nucleotide polymorphism array analysis defines a specific genetic fingerprint for well-differentiated cutaneous SCCs*. J Invest Dermatol, 2009. **129**(6): p. 1562-8.
43. Lambert, S.R., et al., *Metastatic cutaneous squamous cell carcinoma shows frequent deletion in the protein tyrosine phosphatase receptor Type D gene*. Int J Cancer, 2012. **131**(3): p. E216-26.
44. Du, Q.Y., et al., *High STRN Expression Promotes HCC Invasion and Migration but Not Cell Proliferation or Apoptosis through Facilitating Epithelial-Mesenchymal Transition*. Biomed Res Int, 2020. **2020**: p. 6152925.
45. Shao, Y.W., et al., *Cross-species genomics identifies DLG2 as a tumor suppressor in osteosarcoma*. Oncogene, 2019. **38**(2): p. 291-298.
46. Huang, R., et al., *The NCATS BioPlanet – An Integrated Platform for Exploring the Universe of Cellular Signaling Pathways for Toxicology, Systems Biology, and Chemical Genomics*. Frontiers in Pharmacology, 2019. **10**.
47. Agarwal, V., et al., *Predicting effective microRNA target sites in mammalian mRNAs*. Elife, 2015. **4**.
48. Hayward, N.K., et al., *Whole-genome landscapes of major melanoma subtypes*. Nature, 2017. **545**(7653): p. 175-180.
49. Alexandrov, L.B., et al., *The repertoire of mutational signatures in human cancer*. Nature, 2020. **578**(7793): p. 94-101.
50. Tate, J.G., et al., *COSMIC: the Catalogue Of Somatic Mutations In Cancer*. Nucleic Acids Res, 2019. **47**(D1): p. D941-d947.
51. Takahashi, R., et al., *Epigenetic deregulation of Ellis Van Creveld confers robust Hedgehog signaling in adult T-cell leukemia*. Cancer Sci, 2014. **105**(9): p. 1160-9.
52. Mamoor, S., *EVC is differentially expressed in lymph node metastasis in human breast cancer*. OSF Preprints, 2021.
53. Luo, W., et al., *Protein phosphatase 1 regulatory subunit 1A in ewing sarcoma tumorigenesis and metastasis*. Oncogene, 2018. **37**(6): p. 798-809.
54. Yuan, C.L., et al., *Identification of differentially expressed lncRNAs and mRNAs in luminal-B breast cancer by RNA-sequencing*. BMC Cancer, 2019. **19**(1): p. 1171.
55. Wu, L., et al., *Long non-coding RNA LINC01003 suppresses the development of multiple myeloma by targeting miR-33a-5p/PIMI axis*. Leuk Res, 2021. **106**: p. 106565.
56. Klinakis, A. and T. Rampias, *TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection*. EBioMedicine, 2020. **58**: p. 102905.
57. Burtness, B., et al., *Correlation of tumor mutational burden (TMB) with CDKN2A and TP53 mutation in HPV-negative head and neck squamous cell carcinoma (HNSCC)*. 2020, American Society of Clinical Oncology.
58. Zhang, R., et al., *Role of the complement system in the tumor microenvironment*. Cancer Cell Int, 2019. **19**: p. 300.
59. Rahmati Nezhad, P., et al., *Complement Factor D Is a Novel Biomarker and Putative Therapeutic Target in Cutaneous Squamous Cell Carcinoma*. Cancers (Basel), 2022. **14**(2).
60. Johnson, E.M., et al., *Complement Factor H in cSCC: Evidence of a Link Between Sun Exposure and Immunosuppression in Skin Cancer Progression*. Front Oncol, 2022. **12**: p. 819580.
61. Riihila, P., et al., *Complement System in Cutaneous Squamous Cell Carcinoma*. Int J Mol Sci, 2019. **20**(14).

62. Chong, P.K., et al., *Upregulation of plasma C9 protein in gastric cancer patients*. Proteomics, 2010. **10**(18): p. 3210-21.
63. Joshi, V., et al., *Complement component C9 as a new biomarker for esophageal adenocarcinoma*. Journal of Clinical Oncology, 2017. **35**(4_suppl): p. 19-19.
64. Li, L., et al., *Hypoxia restrains the expression of complement component 9 in tumor-associated macrophages promoting non-small cell lung cancer progression*. Cell Death Discov, 2018. **4**: p. 63.
65. Li, G.Z., et al., *COLEC12 regulates apoptosis of osteosarcoma through Toll-like receptor 4-activated inflammation*. J Clin Lab Anal, 2020. **34**(11): p. e23469.
66. Espinal-Enríquez, J., et al., *Genome-wide expression analysis suggests a crucial role of dysregulation of matrix metalloproteinases pathway in undifferentiated thyroid carcinoma*. BMC Genomics, 2015. **16**(1): p. 207.
67. Chang, L.L., et al., *Stromal C-type lectin receptor COLEC12 integrates H. pylori, PGE2-EP2/4 axis and innate immunity in gastric diseases*. Sci Rep, 2018. **8**(1): p. 3821.
68. Li, Q. and Y. Shu, *Role of solute carriers in response to anticancer drugs*. Mol Cell Ther, 2014. **2**: p. 15.
69. Sweet, D.H., *Organic anion transporter (Slc22a) family members as mediators of toxicity*. Toxicol Appl Pharmacol, 2005. **204**(3): p. 198-215.
70. Hu, S., et al., *Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity*. Clin Transl Sci, 2017. **10**(5): p. 412-420.
71. Sági, J.C., et al., *Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma*. BMC Cancer, 2018. **18**(1): p. 704.
72. Sutherland, R., A. Meeson, and S. Lowes, *Solute transporters and malignancy: establishing the role of uptake transporters in breast cancer and breast cancer metastasis*. Cancer Metastasis Rev, 2020. **39**(3): p. 919-932.
73. Ortiz, B., et al., *Deletion of Ptpd and Cdkn2a cooperate to accelerate tumorigenesis*. Oncotarget, 2014. **5**(16): p. 6976-82.
74. Veeriah, S., et al., *The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers*. Proc Natl Acad Sci U S A, 2009. **106**(23): p. 9435-40.
75. Peyser, N.D., et al., *Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer*. PLoS One, 2015. **10**(8): p. e0135750.
76. Holmström, M.O., et al., *The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy*. Leukemia, 2018. **32**(2): p. 429-437.
77. Liu, P., et al., *Immunosuppression by Mutated Calreticulin Released from Malignant Cells*. Mol Cell, 2020. **77**(4): p. 748-760.e9.
78. Miyamoto, R., et al., *Prognostic significance of cyclin D1 amplification and overexpression in oral squamous cell carcinomas*. Oral Oncol, 2003. **39**(6): p. 610-8.
79. Yu, J., et al., *Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma*. Clin Cancer Res, 2019. **25**(21): p. 6511-6523.
80. Rinaldi, J., et al., *The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors*. PLoS One, 2020. **15**(5): p. e0231999.
81. Arao, T., et al., *FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma*. Hepatology, 2013. **57**(4): p. 1407-15.

82. Zhao, R., et al., *Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer*. EBioMedicine, 2016. **8**: p. 30-39.
83. Feng, D.D., et al., *Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia*. J Cell Mol Med, 2011. **15**(10): p. 2164-75.
84. Zhao, D., Y. Sui, and X. Zheng, *MiR-331-3p inhibits proliferation and promotes apoptosis by targeting HER2 through the PI3K/Akt and ERK1/2 pathways in colorectal cancer*. Oncol Rep, 2016. **35**(2): p. 1075-82.